HC Wainwright Weighs in on Gossamer Bio FY2029 Earnings

Gossamer Bio, Inc. (NASDAQ:GOSS) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for Gossamer Bio in a research report issued to clients and investors on Thursday, January 30th. HC Wainwright analyst P. Trucchio anticipates that the company will post earnings per share of $0.59 for the year. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Gossamer Bio’s current full-year earnings is ($0.28) per share.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.04. The company had revenue of $9.48 million for the quarter, compared to the consensus estimate of $4.52 million.

Gossamer Bio Trading Up 3.1 %

Shares of GOSS opened at $0.99 on Friday. The firm has a market cap of $225.15 million, a price-to-earnings ratio of -3.11 and a beta of 1.81. The company has a debt-to-equity ratio of 3.64, a quick ratio of 6.74 and a current ratio of 6.74. Gossamer Bio has a fifty-two week low of $0.50 and a fifty-two week high of $1.60. The firm has a 50 day moving average price of $0.87 and a 200-day moving average price of $0.90.

Institutional Investors Weigh In On Gossamer Bio

A number of hedge funds have recently made changes to their positions in the business. US Bancorp DE purchased a new position in shares of Gossamer Bio in the third quarter worth $39,000. GSA Capital Partners LLP bought a new position in Gossamer Bio in the 3rd quarter worth about $67,000. Algert Global LLC bought a new position in Gossamer Bio in the 2nd quarter worth about $75,000. Sequoia Financial Advisors LLC lifted its stake in Gossamer Bio by 26.7% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 118,500 shares of the company’s stock valued at $117,000 after acquiring an additional 25,000 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in Gossamer Bio by 67.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 310,213 shares of the company’s stock valued at $279,000 after acquiring an additional 124,913 shares during the period. 81.23% of the stock is currently owned by institutional investors.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.